

Rule 3.19A.2

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b> Antisense Therapeutics Limited (ASX: ANP)
ABN 41 095 060 745

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Robert W Moses
<b>Date of last notice</b>	20 December 2019

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct		
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	-		
<b>Date of change</b>	23 December 2019		
<b>No. of securities held prior to change</b>		<b>Shares</b>	<b>Options</b>
	<b>Direct</b>	9,000,000	-
	<b>Indirect</b>	-	-
	<b>Total</b>	<b>9,000,000</b>	-
<b>Class</b>	Unlisted Options		
<b>Number acquired</b>		<b>Shares</b>	<b>Options</b>
	<b>Direct</b>	-	10,000,000
	<b>Indirect</b>	-	-
	<b>Total</b>	-	<b>10,000,000</b>
<b>Number disposed</b>		<b>Shares</b>	<b>Options</b>
	<b>Direct</b>	-	-
	<b>Indirect</b>	-	-
	<b>Total</b>	-	-

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Non-cash, see 'nature of change' below.													
<b>No. of securities held after change</b>	<table border="1"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td><b>Direct</b></td> <td>9,000,000</td> <td>10,000,000</td> </tr> <tr> <td><b>Indirect</b></td> <td>-</td> <td>-</td> </tr> <tr> <td><b>Total</b></td> <td><b>9,000,000</b></td> <td><b>10,000,000</b></td> </tr> </tbody> </table>			Shares	Options	<b>Direct</b>	9,000,000	10,000,000	<b>Indirect</b>	-	-	<b>Total</b>	<b>9,000,000</b>	<b>10,000,000</b>
	Shares	Options												
<b>Direct</b>	9,000,000	10,000,000												
<b>Indirect</b>	-	-												
<b>Total</b>	<b>9,000,000</b>	<b>10,000,000</b>												
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of options as approved by Antisense Therapeutics Limited shareholders at the Annual General Meeting held 11 December 2019													

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – +Closed period

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A



23 December 2019

+ See chapter 19 for defined terms.

Rule 3.19A.2

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b> Antisense Therapeutics Limited (ASX: ANP)
ABN 41 095 060 745

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Mark Diamond
<b>Date of last notice</b>	18 December 2019

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct														
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	-														
<b>Date of change</b>	23 December 2019														
<b>No. of securities held prior to change</b>	<table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td><b>Direct</b></td> <td>4,242,772</td> <td>-</td> </tr> <tr> <td><b>Indirect</b></td> <td>-</td> <td>-</td> </tr> <tr> <td><b>Total</b></td> <td>4,242,772</td> <td>-</td> </tr> </tbody> </table>				Shares	Options	<b>Direct</b>	4,242,772	-	<b>Indirect</b>	-	-	<b>Total</b>	4,242,772	-
	Shares	Options													
<b>Direct</b>	4,242,772	-													
<b>Indirect</b>	-	-													
<b>Total</b>	4,242,772	-													
<b>Class</b>	Unlisted Options														
<b>Number acquired</b>	<table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td><b>Direct</b></td> <td>-</td> <td>14,000,000</td> </tr> <tr> <td><b>Indirect</b></td> <td>-</td> <td>-</td> </tr> <tr> <td><b>Total</b></td> <td>-</td> <td>14,000,000</td> </tr> </tbody> </table>				Shares	Options	<b>Direct</b>	-	14,000,000	<b>Indirect</b>	-	-	<b>Total</b>	-	14,000,000
	Shares	Options													
<b>Direct</b>	-	14,000,000													
<b>Indirect</b>	-	-													
<b>Total</b>	-	14,000,000													
<b>Number disposed</b>	<table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td><b>Direct</b></td> <td>-</td> <td>-</td> </tr> <tr> <td><b>Indirect</b></td> <td>-</td> <td>-</td> </tr> <tr> <td><b>Total</b></td> <td>-</td> <td>-</td> </tr> </tbody> </table>				Shares	Options	<b>Direct</b>	-	-	<b>Indirect</b>	-	-	<b>Total</b>	-	-
	Shares	Options													
<b>Direct</b>	-	-													
<b>Indirect</b>	-	-													
<b>Total</b>	-	-													

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Non-cash, see 'nature of change' below.													
<b>No. of securities held after change</b>	<table border="1"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td><b>Direct</b></td> <td>4,242,772</td> <td>14,000,000</td> </tr> <tr> <td><b>Indirect</b></td> <td>-</td> <td>-</td> </tr> <tr> <td><b>Total</b></td> <td><b>4,242,772</b></td> <td><b>14,000,000</b></td> </tr> </tbody> </table>			Shares	Options	<b>Direct</b>	4,242,772	14,000,000	<b>Indirect</b>	-	-	<b>Total</b>	<b>4,242,772</b>	<b>14,000,000</b>
	Shares	Options												
<b>Direct</b>	4,242,772	14,000,000												
<b>Indirect</b>	-	-												
<b>Total</b>	<b>4,242,772</b>	<b>14,000,000</b>												
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of options as approved by Antisense Therapeutics Limited shareholders at the Annual General Meeting held 11 December 2019													

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – +Closed period

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A



**The CFO Solution**

23 December 2019

+ See chapter 19 for defined terms.

Rule 3.19A.2

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b> Antisense Therapeutics Limited (ASX: ANP)
ABN 41 095 060 745

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr Graham Mitchell
<b>Date of last notice</b>	18 December 2019

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct														
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	-														
<b>Date of change</b>	23 December 2019														
<b>No. of securities held prior to change</b>	<table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th style="width: 30%;"></th> <th style="width: 35%;">Shares</th> <th style="width: 35%;">Options</th> </tr> </thead> <tbody> <tr> <td><b>Direct</b></td> <td>395,550</td> <td>-</td> </tr> <tr> <td><b>Indirect</b></td> <td>-</td> <td>-</td> </tr> <tr> <td><b>Total</b></td> <td><b>395,550</b></td> <td><b>-</b></td> </tr> </tbody> </table>				Shares	Options	<b>Direct</b>	395,550	-	<b>Indirect</b>	-	-	<b>Total</b>	<b>395,550</b>	<b>-</b>
	Shares	Options													
<b>Direct</b>	395,550	-													
<b>Indirect</b>	-	-													
<b>Total</b>	<b>395,550</b>	<b>-</b>													
<b>Class</b>	Unlisted Options														
<b>Number acquired</b>	<table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th style="width: 30%;"></th> <th style="width: 35%;">Shares</th> <th style="width: 35%;">Options</th> </tr> </thead> <tbody> <tr> <td><b>Direct</b></td> <td>-</td> <td>7,000,000</td> </tr> <tr> <td><b>Indirect</b></td> <td>-</td> <td>-</td> </tr> <tr> <td><b>Total</b></td> <td><b>-</b></td> <td><b>7,000,000</b></td> </tr> </tbody> </table>				Shares	Options	<b>Direct</b>	-	7,000,000	<b>Indirect</b>	-	-	<b>Total</b>	<b>-</b>	<b>7,000,000</b>
	Shares	Options													
<b>Direct</b>	-	7,000,000													
<b>Indirect</b>	-	-													
<b>Total</b>	<b>-</b>	<b>7,000,000</b>													
<b>Number disposed</b>	<table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th style="width: 30%;"></th> <th style="width: 35%;">Shares</th> <th style="width: 35%;">Options</th> </tr> </thead> <tbody> <tr> <td><b>Direct</b></td> <td>-</td> <td>-</td> </tr> <tr> <td><b>Indirect</b></td> <td>-</td> <td>-</td> </tr> <tr> <td><b>Total</b></td> <td><b>-</b></td> <td><b>-</b></td> </tr> </tbody> </table>				Shares	Options	<b>Direct</b>	-	-	<b>Indirect</b>	-	-	<b>Total</b>	<b>-</b>	<b>-</b>
	Shares	Options													
<b>Direct</b>	-	-													
<b>Indirect</b>	-	-													
<b>Total</b>	<b>-</b>	<b>-</b>													

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Non-cash, see 'nature of change' below.													
<b>No. of securities held after change</b>	<table border="1"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td><b>Direct</b></td> <td>395,550</td> <td>7,000,000</td> </tr> <tr> <td><b>Indirect</b></td> <td>-</td> <td>-</td> </tr> <tr> <td><b>Total</b></td> <td><b>395,550</b></td> <td><b>7,000,000</b></td> </tr> </tbody> </table>			Shares	Options	<b>Direct</b>	395,550	7,000,000	<b>Indirect</b>	-	-	<b>Total</b>	<b>395,550</b>	<b>7,000,000</b>
	Shares	Options												
<b>Direct</b>	395,550	7,000,000												
<b>Indirect</b>	-	-												
<b>Total</b>	<b>395,550</b>	<b>7,000,000</b>												
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of options as approved by Antisense Therapeutics Limited shareholders at the Annual General Meeting held 11 December 2019													

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – +Closed period

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A



**The CFO Solution**

23 December 2019

+ See chapter 19 for defined terms.

Rule 3.19A.2

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b> Antisense Therapeutics Limited (ASX: ANP)
ABN 41 095 060 745

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Gary W Pace
<b>Date of last notice</b>	8 May 2018

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect		
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Dr G W Pace & Mrs J Hamilton Pace		
<b>Date of change</b>	23 December 2019		
<b>No. of securities held prior to change</b>		<b>Shares</b>	<b>Options</b>
	<b>Direct</b>	-	-
	<b>Indirect</b>	1,236,138	-
	<b>Total</b>	<b>1,236,138</b>	-
<b>Class</b>	Unlisted Options		
<b>Number acquired</b>		<b>Shares</b>	<b>Options</b>
	<b>Direct</b>	-	-
	<b>Indirect</b>	-	7,000,000
	<b>Total</b>	-	<b>7,000,000</b>
<b>Number disposed</b>		<b>Shares</b>	<b>Options</b>
	<b>Direct</b>	-	-
	<b>Indirect</b>	-	-
	<b>Total</b>	-	-

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Non-cash, see 'nature of change' below.													
<b>No. of securities held after change</b>	<table border="1"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td><b>Direct</b></td> <td>-</td> <td>-</td> </tr> <tr> <td><b>Indirect</b></td> <td>1,236,138</td> <td>7,000,000</td> </tr> <tr> <td><b>Total</b></td> <td><b>1,236,138</b></td> <td><b>7,000,000</b></td> </tr> </tbody> </table>			Shares	Options	<b>Direct</b>	-	-	<b>Indirect</b>	1,236,138	7,000,000	<b>Total</b>	<b>1,236,138</b>	<b>7,000,000</b>
	Shares	Options												
<b>Direct</b>	-	-												
<b>Indirect</b>	1,236,138	7,000,000												
<b>Total</b>	<b>1,236,138</b>	<b>7,000,000</b>												
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of options as approved by Antisense Therapeutics Limited shareholders at the Annual General Meeting held 11 December 2019													

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – +Closed period

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A



23 December 2019

+ See chapter 19 for defined terms.



Rule 3.19A.2

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b> Antisense Therapeutics Limited (ASX: ANP)
ABN 41 095 060 745

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	William Goolsbee
<b>Date of last notice</b>	20 December 2019

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct														
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	-														
<b>Date of change</b>	23 December 2019														
<b>No. of securities held prior to change</b>	<table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td><b>Direct</b></td> <td>1,099,243</td> <td>-</td> </tr> <tr> <td><b>Indirect</b></td> <td>-</td> <td>-</td> </tr> <tr> <td><b>Total</b></td> <td><b>1,099,243</b></td> <td>-</td> </tr> </tbody> </table>				Shares	Options	<b>Direct</b>	1,099,243	-	<b>Indirect</b>	-	-	<b>Total</b>	<b>1,099,243</b>	-
	Shares	Options													
<b>Direct</b>	1,099,243	-													
<b>Indirect</b>	-	-													
<b>Total</b>	<b>1,099,243</b>	-													
<b>Class</b>	Unlisted Options														
<b>Number acquired</b>	<table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td><b>Direct</b></td> <td>-</td> <td>7,000,000</td> </tr> <tr> <td><b>Indirect</b></td> <td>-</td> <td>-</td> </tr> <tr> <td><b>Total</b></td> <td>-</td> <td><b>7,000,000</b></td> </tr> </tbody> </table>				Shares	Options	<b>Direct</b>	-	7,000,000	<b>Indirect</b>	-	-	<b>Total</b>	-	<b>7,000,000</b>
	Shares	Options													
<b>Direct</b>	-	7,000,000													
<b>Indirect</b>	-	-													
<b>Total</b>	-	<b>7,000,000</b>													
<b>Number disposed</b>	<table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td><b>Direct</b></td> <td>-</td> <td>-</td> </tr> <tr> <td><b>Indirect</b></td> <td>-</td> <td>-</td> </tr> <tr> <td><b>Total</b></td> <td>-</td> <td>-</td> </tr> </tbody> </table>				Shares	Options	<b>Direct</b>	-	-	<b>Indirect</b>	-	-	<b>Total</b>	-	-
	Shares	Options													
<b>Direct</b>	-	-													
<b>Indirect</b>	-	-													
<b>Total</b>	-	-													

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Non-cash, see 'nature of change' below.													
<b>No. of securities held after change</b>	<table border="1"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td><b>Direct</b></td> <td>1,099,243</td> <td>7,000,000</td> </tr> <tr> <td><b>Indirect</b></td> <td>-</td> <td>-</td> </tr> <tr> <td><b>Total</b></td> <td><b>1,099,243</b></td> <td><b>7,000,000</b></td> </tr> </tbody> </table>			Shares	Options	<b>Direct</b>	1,099,243	7,000,000	<b>Indirect</b>	-	-	<b>Total</b>	<b>1,099,243</b>	<b>7,000,000</b>
	Shares	Options												
<b>Direct</b>	1,099,243	7,000,000												
<b>Indirect</b>	-	-												
<b>Total</b>	<b>1,099,243</b>	<b>7,000,000</b>												
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of options as approved by Antisense Therapeutics Limited shareholders at the Annual General Meeting held 11 December 2019													

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – +Closed period

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A



23 December 2019

+ See chapter 19 for defined terms.